Plain-English translation of NCT07536841 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is testing a new diagnostic tool called the Odesa Criteria 2026 (OC26) to see if it can reliably help doctors diagnose autoimmune pancreatitis—a rare condition where the pancreas becomes inflamed by the body's own immune system. The tool uses a scoring system that combines information from blood tests, imaging scans, clinical symptoms, and sometimes tissue samples to give doctors a clear, consistent way to identify this disease. Researchers want to confirm that this tool works well in real-world clinical practice and could help doctors diagnose the condition more accurately.
Autoimmune pancreatitis is difficult to diagnose because its symptoms overlap with other pancreatic conditions, including pancreatic cancer and chronic pancreatitis. This study exists to validate a practical, organized diagnostic tool that could help doctors confidently identify autoimmune pancreatitis and avoid unnecessary confusion with other serious conditions.
You likely qualify if…
You likely don't qualify if…
As a participant, you would not receive any new treatments or medications. Instead, researchers would review your existing medical information—including your clinical history, blood tests, imaging results, and any tissue biopsies—and apply the new Odesa Criteria 2026 scoring system to your case. This is an observational study, meaning doctors are simply collecting and analyzing data from your standard medical care to see how well the diagnostic tool works in practice.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Ukraine
Sponsor
Military Medical Clinical Center of the Southern Region, Ukraine
Enrollment target
~82 participants
Started
May 2026
Primary completion
May 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Oleg Dovbenko, MD, PhD
Odesa Regional Clinical Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.